SAN DIEGO , Aug. 6, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS ), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that members of the management team will present at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13 th at 8:30 a.
m. ET . A replay of the live presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.
regulusrx.com/events and archived for 90 days following the presentation date. About Regulus Regulus Therapeutics Inc.
(Nasdaq: RGLS ) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in San Diego, CA.
Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the Company's RGLS8429 program and preclinical pipeline, the potential that RGLS8429 may be eligible for an Accelerated Approval pathway, the expected timing for reporting topline data, an.